The Pre-Eclampsia drugs in development market research report provides comprehensive information on the therapeutics under development for Pre-Eclampsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pre-Eclampsia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pre-Eclampsia and features dormant and discontinued products.
GlobalData tracks 12 drugs in development for Pre-Eclampsia by 12 companies/universities/institutes. The top development phase for Pre-Eclampsia is preclinical with five drugs in that stage. The Pre-Eclampsia pipeline has 11 drugs in development by companies and one by universities/ institutes. Some of the companies in the Pre-Eclampsia pipeline products market are: UMass Chan Medical School, Ferring International Center and Gmax Biopharm.
The key targets in the Pre-Eclampsia pipeline products market include Vascular Endothelial Growth Factor Receptor 1 (Fms Like Tyrosine Kinase 1 or Tyrosine Protein Kinase Receptor FLT or Tyrosine Protein Kinase FRT or Vascular Permeability Factor Receptor or VEGFR1 or FLT1 or EC 2.7.10.1), Relaxin Receptor 1 (Leucine Rich Repeat Containing G Protein Coupled Receptor 7 or Relaxin Family Peptide Receptor 1 or LGR7 or RXFP1), and Marinobufagenin (MBG).
The key mechanisms of action in the Pre-Eclampsia pipeline product include Relaxin Receptor 1 (Leucine Rich Repeat Containing G Protein Coupled Receptor 7 or Relaxin Family Peptide Receptor 1 or LGR7 or RXFP1) Agonist with two drugs in Discovery. The Pre-Eclampsia pipeline products include three routes of administration with the top ROA being Intravenous and six key molecule types in the Pre-Eclampsia pipeline products market including Monoclonal Antibody, and Small Molecule.
Pre-Eclampsia overview
Hypertension during pregnancy is termed pre-eclampsia. It generally occurs during the second trimester or after giving birth. Although there is no exact cause but stress, abnormal placentation is believed to lead to pre-eclampsia. Obesity, underlying diseased conditions hypertension, diabetes, kidney disease, or genetic causes may also lead to this. When pathologically examined high levels of protein in the urine (proteinuria), renal insufficiency, and thrombocytopenia are observed. Headache, SOB, blurred vision, nausea and vomiting, pain in the abdomen are common complaints. Premature delivery of the baby is considered in emergency cases and in mild to moderate cases blood pressure management with beta-blockers such as labetalol, or calcium channel blockers nifedipine given.
For a complete picture of Pre-Eclampsia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
